Photocure Valuation
Is PHOO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of PHOO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: PHOO (NOK57.7) wird unter unserer Schätzung des Fair Value (NOK229.56) gehandelt.
Deutlich unter dem Marktwert: PHOO wird um mehr als 20 % unter dem Marktwert gehandelt.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PHOO?
Other financial metrics that can be useful for relative valuation.
What is PHOO's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | kr1.79b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.4x |
Enterprise Value/EBITDA | -591.1x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does PHOO's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.4x | ||
ANCR Animalcare Group | 1.8x | 4.3% | UK£125.0m |
APH Alliance Pharma | 1.2x | 6.3% | UK£199.9m |
REDX Redx Pharma | 3.9x | -37.6% | UK£16.5m |
AGY Allergy Therapeutics | 2.6x | n/a | UK£135.8m |
PHOO Photocure | 3.9x | 15.7% | kr1.8b |
Price-To-Sales gegen Gleichaltrige: PHOO ist ein guter Wert, wenn man sein Price-To-Sales Verhältnis (4x) mit dem Durchschnitt der anderen Unternehmen (6.6x) vergleicht.
Price to Earnings Ratio vs Industry
How does PHOO's PE Ratio compare vs other companies in the GB Pharmaceuticals Industry?
Price-To-Sales gegen Industrie: PHOO ist teuer, wenn man sein Price-To-Sales Verhältnis (3.5x) mit dem European Pharmaceuticals Branchendurchschnitt (3x) vergleicht.
Price to Sales Ratio vs Fair Ratio
What is PHOO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 3.9x |
Fair PS Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Sales Fair Ratio von PHOO für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.